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The United Nations (UN) Millennium
Development Goals (MDGs) expire in
2015. A high-level panel, appointed to
discuss the global development agenda
post-2015, reported back in May 2013
with its recommendations. These are likely
to prove extremely important for deter-
mining the global health budget over the
coming decade. Who the ‘‘winners’’—
those who will benefit from UN endorse-
ment and enhanced funding—and the
‘‘losers’’—those not receiving such recog-
nition or resources—will be in the new
agenda is not yet decided, but certain
parties hope that this time around NTDs
will gain a special mention.
The MDGs, established in 2000, gave a
new prominence to the health issues
affecting the poor. However, the spotlight
they provided was restricted and derived
from a top-down process of deliberation,
rather than informed by inclusive analysis
and/or a thorough prioritisation of devel-
opment needs. Subsequently, the narrowly
focused and largely sector-specific MDGs
left gaps in coverage and failed to realise
synergies between the foci covered by the
goals (education, health, poverty, and
gender) [1]. MDG 6 in particular—
‘‘combat HIV/AIDS, malaria and other
diseases’’—sidelined many of the commu-
nicable and non-communicable diseases
that perpetuate the cycle of poverty in
developing countries. And yet, the very act
of naming HIV/AIDS and malaria raised
the profile of these diseases immeasurably.
It stimulated a reconfiguration of official
development assistance for health. Global
health initiatives such as the Global Fund
to Fight AIDS, Tuberculosis and Malaria
(GFATM) and the President’s Emergency
Plan for AIDS Relief (PEPFAR) ushered
in an era of vertical aid on an unprece-
dented scale and diverted resources away
from existing health programmes [2]. In
this funding climate, diseases were pitted
against one another and advocacy groups
were left to argue that it was their disease
being referred to in the ambiguous
wording ‘‘other diseases.’’ In this respect,
the case of tuberculosis is instructive; the
success of the tuberculosis campaigning
was such that it is now widely assumed
that it too received a special mention in
the MDG 6. Of course, parallel to this
misapprehension, tuberculosis was consid-
ered so central to the GFATM that it was
even incorporated into the name; the
extent to which this is due to lobbying or
to the specific interactions between HIV/
AIDS and tuberculosis has not been
established. Clearly, however, effective
networking and alliance building can blur
the boundaries of the MDGs and raise the
profiles of diseases.
Establishing the NTDs
The 17 NTDs identified by the World
Health Organization (WHO) represent
some of MDG6’s ‘‘other diseases.’’ This
neglected tag stems from the disparity
between the attention and funding these
diseases receive (0.6% of official develop-
ment assistance for health) and their
catastrophic impact in terms of disability-
adjusted life years (DALYs) [3,4]. The
perception of the neglect of these diseases
is exacerbated when one considers the
importance of the role the NTDs play as
drivers and indicators of poverty [5],
undermining efforts to meet the targets
of virtually all the other goals [6,7]. One
could even argue that their ubiquity as
relatively invisible cross-cutting drivers of
poverty has paradoxically limited concert-
ed efforts to focus on them.
The case for including NTDs in the
post-2015 agenda has been building since
their ostensible omission from MDG 6,
which served as a call to arms for a group
of concerned stakeholders, who have since
contributed to a series of landmark
initiatives that have placed NTDs firmly
on the international agenda.
The term ‘‘neglected diseases’’ was
coined by Kenneth Warren of the Rock-
efeller Foundation in the early 1980s
through his Great Neglected Disease
Initiative. The concept was revived in
2003, when the first of two WHO/
Deutsche Gesellschaft fu¨r Technische Zu-
sammenarbeit (GTZ) meetings was con-
vened to float the idea that these diseases
should be taken forward as a group,
because they shared considerable geo-
graphical overlap, were in many cases
syndemic, and could better be addressed
by creating synergies between existing
vertical programmes [8,9]. Also in 2003,
the Drugs for Neglected Diseases initiative
(DNDi) and the Foundation for Innova-
tive Diagnostics (FIND) were established.
In 2005, a second WHO/GTZ meeting
was held, WHO set up a department for
Neglected Tropical Diseases, and a
group of previously obscure ‘‘parasitic
diseases’’ secured a mention in the
Commission for Africa Report [10]. In
2006, the Global Network for Neglected
Tropical Diseases (focusing on the seven
most prevalent NTDs) was formed, and
integrated NTD control was awarded a
Congressional earmark in the United
States. In 2007, the specialist journal
PLOS Neglected Tropical Diseases—the re-
sult of a collaboration between the Bill &
Melinda Gates Foundation and the
Public Library of Science—published its
first article online. In 2010, WHO
released its First Report on the NTDs,
pinning down the 17 focal diseases we
now know by the shorthand ‘‘NTDs’’
[11]. In 2012, WHO followed up that
landmark document with a roadmap for
action [12], and the London Declaration on
Neglected Tropical Diseases was endorsed by
a wide range of stakeholders [13]. In
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May 2013, a milestone WHO resolution
on the NTDs was adopted [14].
Alongside these events, the NTDs
secured unprecedented funding from
traditional and non-traditional sources.
Bilateral donors, the UK’s Department
for International Development (DFID),
and the US Agency for International
Development (USAID) remain impor-
tant. However, in terms of volume, it
has been the philanthropic contributions
of the Bill & Melinda Gates Foundation
(pledging US $363 million over the next
five years) driving research agendas and
the in-kind drug donations provided by
the pharmaceutical industry (worth be-
tween US $2–3 billion annually [15])
that have shaped mass drug administra-
tion programmes that have proved
decisive in changing the fortunes of
several of the NTDs. The galvanising
force behind this change in fortune for
the NTDs has been new forms of
partnership between the public and
private sectors.
Already the fruits of the public-private
partnership approach are being felt, with
gains in NTD control providing hope that
elimination may be a possibility for many
of the diseases [16,17]. The success has
been such that the WHO Secretary
General, Dr. Margaret Chan, recently
referred to the story of the NTDs in the
21st century as one of ‘‘rags to riches’’
[18]. In this extraordinary reversal of
fortunes, the centrality of branding cannot
be downplayed [15,19]; where once 17
disparate diseases (caused by different
pathogens and with varying susceptibility
to control or elimination) were easily
ignored, under the rubric of NTDs, they
have become a clarion call for pulling the
world’s ‘‘bottom billion’’ out of poverty
[20].
Do the MDGs Really Matter?
Given the recent meetings of the high-
level forum to discuss the post-2015
agenda and the high-profile debate around
both the success or otherwise of the
MDGs, and what might supersede them,
it is significant to reflect that the strides
made in NTD control in the first decade of
the 21st century were made despite the
diseases’ effective omission from the
MDGs. Does this mean that getting onto
the post-2015 agenda is immaterial to the
NTDs? In this light, it is instructive to look
at exactly who has endorsed the London
Declaration on NTDs. The bulk of
signatories are pharmaceutical companies,
DNDi, and the Bill & Melinda Gates
Foundation; the only traditional donors to
sign are USAID, DFID, and the World
Bank. It is possible then that global health
post-2015 might be driven by new sets of
partnerships and actors. That said, the
emulation of MDG-style time-bound tar-
gets in both the WHO Roadmap and the
London Declaration’s ‘‘scorecard’’ format
suggests the NTD community has been
deeply influenced by the UN’s original
goals. In addition, it is no coincidence that
the notion of the NTDs included as part of
a ‘‘gang of four’’ expanding the current
‘‘big three’’, based on their comparable
burden of DALYs, was floated in a series
of policy papers co-authored by three
scientists intent on influencing the debate
around priorities in the wake of the
original MDG decision [6,21].
These scientist-influencers—Peter J.
Hotez, David Molyneux, and Alan Fen-
wick (with Lorenzo Savioli and others)—
helped to develop the rationale for the
NTDs to be viewed as an aggregate group.
Moreover, they persuasively argued that
mass drug administration for the seven
most prevalent NTDs represented one of
the ‘‘best buys’’ in global public health,
presenting the evidence to accompany
their argument in the form of statistics,
case studies, and pricing scenarios (US
$0.50–0.79 per person, per year) [8,21].
And yet, despite developing a compelling
business case for the NTDs to go it alone
in the wake of their effective omission from
the MDGs, the policy papers released
post-2000 were explicit that the ideal
scenario was for NTD control to be
integrated into broader health pro-
grammes, specifically those for the ‘‘big
three’’ [22,23]. Aware of the financial
benefits that flow through the MDG name
check, the authors were open in their
desire to see an NTD focus incorporated
into global health initiatives, the GFATM
and PEPFAR, or better yet, an initiative
solely focused on the NTDs [24].
Finally, it is pertinent that the NTD
policy papers repeatedly depicted the
NTDs as direct hindrances to the attain-
ment of the MDGs; conversely, tackling
them head-on was portrayed as directly
beneficial to seven out of the eight goals
[6]. In short, the NTD lobby has never
been disinterested in the MDGs. They are
fully cognisant of the ramifications of the
NTDs’ effective omission from MDG 6.
They have spent the last decade trying to
counter the ill effects, drawing on new
partners and new models to ensure a stake
in the post-MDG policy process, regard-
less of the direction that might take.
Post-2015
The MDGs served to entrench an
established tendency for donors to work
in disease silos and have been critiqued
accordingly. However, whatever hope
there is for drastic change in the post-
2015 development agenda, the MDG
legacy will not be easily overturned
(GFATM, vertical programmes, institu-
tions, and long-term commitments will not
be willingly dismantled). In the revised
post-2015 agenda, there is at least the
sense that we must move away from
mortality-based ways of prioritising global
health needs. In this respect, the NTD
lobbyists such as the WHO, Global
Network, and indeed PLOS Neglected Trop-
ical Diseases itself, have been massively
influential, breathing new life into DALYs,
and, by turn, opening the door for more
nuanced indicators of good health to be
accepted—quality-adjusted life years or
even average life expectancies [4]. Indeed,
the recently released a report of the high-
level panel on the post-2015 development
agenda (mentioned in the introduction)
includes an ‘‘illustrative goal’’ for health
that will ‘‘ensure healthy lives’’ and
explicitly names the NTDs alongside
HIV/AIDS, tuberculosis, malaria, and
non-communicable diseases [25]. Hope-
fully this constellation of actors, the
emergence of new perspectives on health,
and the publication of the New Global
Partnership Report will convince member
states to transform into stakeholders.
One ‘‘advantage’’ that the NTDs may
have in a more enlightened and nuanced
post-MDG era (with regards to develop-
ment as well as to health), is that, by their
very nature, they ‘‘undermine healthy
lives’’ and cut across and threaten to
undermine multiple silos of MDGs. This
suggests a potentially fruitful bifurcated
approach where focusing on NTDs can
help make concrete inroads into reaf-
firmed or tweaked post-2015 MDGs, or
NTDs can be used to articulate a set of
goals that do not represent silos as targets
to be met, but rather represent the
strengthening of the institutions we need
to manage the complex social, economic,
environmental, and health systems that
interact to shape future development. The
former approach serves to underline the
imperative to deal with NTDs if we are to
make further progress. The latter, and
preferable, approach can use the NTDs as
a prompt to think of the goals not only as a
clarion call, but also as an approach to the
future of international development.
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